The U.S.

U.S. Digital Pathology Market

is valued at

USD 334.3 Million in 2023

and is projected to reach a value of

USD 898.2 Million by 2032

at a CAGR (Compound Annual Growth Rate) of

9.5%

between 2024 and 2032.

Key Highlights of U.S. Digital Pathology Market

• The Scanners segment significantly contributed to the market’s expansion, constituting over 44.8% of the overall revenue share in 2023
• Based on Type, the Human Pathology segment accounted for the largest market share in 2023
• In 2023, the Drug Discovery Category dominated the market with around 54.8% share.
• Pharmaceutical and biotechnology industries have played a major role in driving the expansion of U.S. Digital Pathology in the United States. These organizations are essential players in pushing the use of U.S. Digital Pathology technology, mostly because of a number of significant influencing variables.

{{bar_graph}}

U.S. U.S. Digital Pathology Market Overview

Modern medical technology called "U.S. Digital Pathology" entails digitizing conventional pathology procedures. This field combines imaging, computer science, and pathology to improve tissue sample analysis and illness diagnosis. Glass slides holding tissue samples are transformed into digital images in U.S. Digital Pathology so they can be electronically viewed, examined, and archived. In the realm of pathology, this innovative approach has various advantages, such as increased accessibility, efficiency, and accuracy. Pathologists diagnose patients by looking at tissue samples under a microscope in the conventional profession of pathology. This approach has many drawbacks despite its great effectiveness. In summary, U.S. Digital Pathology offers better accessibility, efficiency, and accuracy for disease diagnosis and treatment, making it a breakthrough in the medical industry. U.S. Digital Pathology is expected to become more important in healthcare as technology develops, eventually helping patients by enabling faster and more accurate diagnoses.

{{CountryImage}}

The global

U.S. Digital Pathology market

can be categorized as Product Type, Type, Application, End User, and Region.

U.S. Digital Pathology Market: Product Type Overview

In 2023, the Scanners dominated the market with a 44.8% share and is estimated to continue its dominance during the forecast period. The Product segment is separated into Scanners, Software, and Storage Systems. Scanners are essential to the U.S. Digital Pathology industry because they help turn conventional pathology procedures into a more productive and cutting-edge discipline. These gadgets are made to take clear pictures of glass slides with tissue samples on them and then digitize the photographs. There are many benefits to digitizing pathology slides, such as better workflow, increased professional collaboration, and the possibility of more accurate diagnosis. Advanced medical equipment called U.S. Digital Pathology scanners is used to digitize glass slides that hold tissue samples. To capture microscopic details, they use high-resolution imaging equipment, which makes it possible for pathologists to view and examine these samples on computer displays. This technology makes pathology data accessible at a distance, makes expert collaboration easier, and improves diagnosis accuracy.

U.S. Digital Pathology Market: Application Overview

In 2023, the Human Pathology dominated the market and is estimated to continue its dominance during the forecast period with 68.1% share. The Type segment is categorized into Human Pathology, and Veterinary Pathology. Compared to veterinary pathology items, human pathology goods are significantly more popular in the U.S. Digital Pathology market. Human pathology, or the study and identification of illnesses in human tissues and specimens, is a major area of focus for the science of pathology. Therefore, the primary forces behind the need for U.S. Digital Pathology solutions, such as scanners, software, and storage systems, are the requirements of clinical laboratories and healthcare facilities that place a high priority on patient care. A significant development has occurred in the field of veterinary medicine in recent years. Giving animals and pets top-notch medical treatment is becoming more and more crucial. U.S. Digital Pathology ensures fast and precise detection of animal diseases, which can enhance veterinary practices' diagnostic capabilities.

U.S. Digital Pathology Market: Application Overview

In 2023, the Drug Discovery Category dominated the market with around 54.8% share and is estimated to continue its dominance during the forecast period. The Application segment is categorized into Drug Discovery, Disease Diganosis, and Training and Education. Digitizing conventional glass pathology slides into high-resolution digital pictures is known as U.S. Digital Pathology. Computer technology is used for the management, analysis, and storage of these digital photos. It makes it easier to share, examine, and analyze pathology specimens remotely, which improves diagnosis precision and yields new research insights. A number of variables are driving the expansion of U.S. Digital Pathology in drug discovery in the United States. First off, by simplifying the research procedure, U.S. Digital Pathology speeds up the medication discovery process. The rapid examination and comparison of hundreds of tissue samples by researchers speed up the process of identifying possible targets and therapeutic candidates. Additionally, it encourages cooperation amongst professionals who are spread geographically, making data sharing and group problem-solving easier.

Key Trends

1. Scanners are becoming more and more popular in the U.S. Digital Pathology industry. An important stage in the digitization of pathology workflows is the conversion of glass slides into high-resolution digital images, which is made possible by this equipment. There has been a noticeable growth in the use of advanced scanning technologies due to the growing need for U.S. Digital Pathology solutions, which is being driven by the need for remote access to pathological data and enhanced diagnosis accuracy.
2. When it comes to the U.S. Digital Pathology market in the United States, human pathology goods are far more popular than veterinary pathology products. A significant component of the science of pathology is devoted to the study and diagnosis of diseases in human tissues and specimens, which is known as human pathology. Therefore, the needs of clinical laboratories and healthcare facilities that prioritize patient care are the main drivers of demand for U.S. Digital Pathology solutions, including scanners, software, and storage systems.
3. Drug discovery category had a major share. The rapid examination and comparison of hundreds of tissue samples by researchers speed up the process of identifying possible targets and therapeutic candidates. Additionally, it encourages cooperation amongst professionals who are spread geographically, making data sharing and group problem solving easier. Cost-effectiveness is also quite important diseases, cancer, and orthopedic disorders become more common, fueling this markets expansion.

Premium Insights

The political aspects of the market for U.S. Digital Pathology include laws, rules, and stability of the government. Many regulations apply to the healthcare industry in the United States, including those that deal with data privacy and medical equipment. Any modifications to these rules may have an impact on how U.S. Digital Pathology solutions are created, approved, and used. The United States' aging population is driving up demand for pathology and other healthcare services. An elderly population can have its requirements met by U.S. Digital Pathology through more effective and precise diagnostics. Cultural variables may influence the readiness of patients to adopt U.S. Digital Pathology treatments. It is becoming more and more crucial in the healthcare industry to guarantee that U.S. Digital Pathology solutions are inclusive of a wide range of patient demographics. Digital cameras and high-resolution scanners are examples of imaging technology that has advanced technologically, improving the effectiveness and quality of U.S. Digital Pathology image acquisition. One important technological development in U.S. Digital Pathology is the combination of AI and machine learning. Pathologists can benefit from AI powered algorithms in image analysis, diagnosis, and predictive analytics.

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool:

Vantage Point

Market Dynamics

The growing desire for better healthcare outcomes and more effective diagnostic procedures is a major factor propelling the U.S. Digital Pathology market. This dynamic is driven by a number of interrelated elements that all help the nations acceptance and spread of U.S. Digital Pathology solutions. U.S. Digital Pathology adoption in the US is mostly motivated by the healthcare industrys unwavering quest for better patient outcomes, more efficient diagnostic procedures, and increased operational effectiveness. The growing need for distant and decentralized healthcare services, which is being driven by the COVID-19 pandemic, the need for telemedicine, and the desire for more patient-centric treatment, is another important reason propelling the U.S. Digital Pathology market. This drive is pushing the nations adoption of U.S. Digital Pathology solutions and changing the face of healthcare delivery.

The complicated legal environment and compliance issues related to the use and integration of U.S. Digital Pathology solutions in healthcare settings are major barriers to the growth of the U.S. Digital Pathology market. These forces, which are fueled by the need for standardization, data security concerns, and strict regulatory constraints, provide challenges to the smooth adoption of U.S. Digital Pathology technology. The growing application of artificial intelligence (AI) and machine learning in pathology is a growth factor for the U.S. Digital Pathology market. It offers chances for innovation, increased diagnosis accuracy, and efficiency gains. The image analysis tasks that AI and machine learning algorithms excel at make them indispensable instruments in U.S. Digital Pathology.

Competitive Landscape

The key companies in the market are majorly focusing on partnerships and collaborations, mergers and acquisitions, and new product launch. In March 2023, A new alliance in U.S. Digital Pathology is being announced by Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnoses, and Corista, a leading provider of clinical, research, and educational U.S. Digital Pathology image management solutions. Pathologists will be able to devote more of their time to complex case work by integrating Qritives artificial intelligence modules with Coristas DP3 image management platform through this agreement. Computational modules are able to quantify IHC signals, screen for colon and prostate malignancies, and identify lymph node metastases thanks to the unified solution.

Recent Market Developments

• In September 2023, Israels leading healthcare provider, Clalit Health Services, will use the U.S. Digital Pathology solution from the international medical imaging IT and cybersecurity business sector. The product was marketed by VaRay Oncology Systems, Sectras Israeli distribution partner. It seeks to streamline the pathologists at Clalits review and collaboration process, resulting in more accurate cancer diagnosis.
• In April 2023, An agreement was made to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and Lunits suite of AI pathology products. Indica Labs is a market leader in quantitative U.S. Digital Pathology and image management innovations. Lunit is a leading medical AI software platform company focused on cancer biomarkers. Leading precision oncology company Guardant Health is already using the combination solution.
• In March 2023, the leading supplier of whole slide imaging systems, Hamamatsu Photonics K.K., has teamed with Agilent Technologies Inc. to integrate their NanoZoomer line, which includes the S360MD Slide scanner system, into the Agilent end-to-end U.S. Digital Pathology solution.